Visit other SMART + STRONG sites:
POZ • REAL HEALTH • TU SALUD
Subscribe to:
• E-newsletters
• POZ magazine
POZ Personals
Sign In / Join		 Username:
 Password:
Back to home » Top Stories » CROI 2008
CROI 2008 15th Conference on Retroviruses and Opportunistic Infections
Boston, MA
February 3-8, 2008

AIDS Survival: Progress Not Perfection

February 5, 2008

At the 15th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, David Evans talks with Douglas Ward, MD, about success in controlling AIDS-related complications and progress still to be made.

 

 



8 1/2 minutes. Click here to view the transcript.

NEW! Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

Ray, , 2008-02-05 20:18:39
Hello David, This was a very good and informative interview. Thanks for sharing it with us.

comments 1 - 1 (of 1 total)    


Our general CROI conference coverage was sponsored by Abbott Laboratories, Boehringer Ingelheim and Gilead Sciences.

Additional funding, to support news and video coverage of women's issues at CROI, was provided by Tibotec Therapeutics.

More from CROI 2008
Starting and Switching Treatment
February 9, 2008

Durable Efficacy and Safety With Isentress Treatment

February 7, 2008

Durable Efficacy Seen in Studies of New NNRTI Intelence

Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosing

February 6, 2008

TDM-Guided PI Dose Increases of Limited Benefit

February 5, 2008

Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potency

Epzicom Comparable to Truvada as First-Line NRTI Choice

February 4, 2008

Norvir/Reyataz Comparable to Kaletra for First-Line Therapy



HIV/AIDS Complications and Treatment Side Effects
February 4, 2008

Abacavir, Didanosine Linked to Increased Heart Attack Risk

Sexual Reinfection With HCV Following Treatment



Experimental HIV Drugs
February 12, 2008

VIRxSYS Gene Therapy Makes Progress

February 9, 2008

Prezista Effective and Safe in Positive Kids

February 7, 2008

Nanotechnology May Yield Long-Lasting Meds

February 4, 2008

Vicriviroc Shows Well in Treatment-Experienced Patients



HIV Transmission and Prevention
February 9, 2008

Good Bacteria Reduces Vaginal HIV Levels

February 6, 2008

Male Circumcision Doesn't Reduce Women's HIV Risk



Expert Interviews
February 12, 2008

Women & HIV Treatment

World of Prevention: Vaccines and More

Condom-Free Sex? Controversial Swiss Declaration

February 11, 2008

New Hope for Treatment Experienced

February 8, 2008

HIV & Your Heart: Part I

HIV & Your Heart: Part II

Morris Jackson: Survivor and Treatment Activist

February 7, 2008

Prevention and Women: HIV-positive and HIV-negative

February 6, 2008

Refining HIV Treatment for New Med Takers

February 5, 2008

AIDS Survival: Progress Not Perfection


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy